Comparable to the 2020 resolution, Novartis AG’s $25 million 2016 civil resolution Together with the SEC involved inappropriate sponsorships of HCPs to conferences and incorrect payments to HCPs to collect “healthcare info.” The truth that Novartis is now dealing with a substantially bigger—and legal—resolution for equivalent misconduct m